Clinical trial
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced…
NCT00302757 · University Hospital Tuebingen, Other · Completed
Key facts
| NCT number | NCT00302757 |
|---|---|
| Title | Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma |
| Official title | Multicenter Phase I/II Study of Radioimmunotherapy With 90Y-ibritumomab Tiuxetan in a Nonmyeloablative Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation From HLA-identical Donors in Patients With Advanced Non-Hodgkin Lymphoma |
| Lead sponsor | University Hospital Tuebingen, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | Radioimmunotherapy, allogeneic hematopoietic cell transplantation |
| Enrollment | 60 |
| Start date | Mar 1, 2006 |
| Completion | Jul 1, 2011 |
| First posted | Mar 14, 2006 |
| Last update posted | May 29, 2014 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: